2017518 IARCINTERNATIONALAGENCYFORRESEARCHONCANCER

Youarehere:Home

IARCNews Fea turedNew s

WorldCancerDay2017
LaunchoftheInternationalCancerSurvival IARCatWorldCancerCongress2016
Benchmarkingwebsite BreastCancerAwarenessMonth
TheIARCHandbookonBodyFatness
16/05/2017
TheIARCMonographonHot
The International Agency for Research beverages
on Cancer (IARC) is pleased to TheIARCMonographonGlyphosate
announce the launch of the
International Cancer Survival
Benchmarking website. Incorporating
the most uptodate populationbased
cancersurvivaldataavailable,thisnew
platform will provide a comprehensive
view of cancer survival estimates,
alongside incidence and mortality, in
highincomecountriesandcountriesintransition.Aimedat CANCERRESEARCH
researchers, policymakers, and public health specialists, FORCANCERPREVENTION
the website brings together three international landmark
projects: SURVMARK2, SURVCAN3, and SURVPOOL, in
order to move towards better outcomes after cancer
diagnosisforall.

Visitthewebsite

Launchofnewguidelinesforbiobanksdedicatedto GLOBALCANCEROBSERVATORY

cancerresearch
15/05/2017
The International Agency for Research
on Cancer (IARC) is pleased to
announce the publication of new
guidelines and recommendations for EVALUATIONOFHUMAN
biobanks. The publication, Common CARCINOGENS(Monographs)
Minimum Technical Standards and
Protocols for Biobanks Dedicated to
Cancer Research, provides essential
guidanceforbiobanksnotonlyinhigh
income countries but also in low and
middleincome countries. The recommendations are based
onvalidatedand/orevidencebasedguidelines.
IARCHANDBOOKSOF
Readmore ,SeeIARCTechnicalPublication44 CANCERPREVENTION

Aglobalcancersurveillanceframeworkwithin
noncommunicablediseasesurveillance:makingthe
caseforpopulationbasedcancerregistries
08/05/2017
AnewstudybyresearchersfromtheInternationalAgency WHO/IARCCLASSIFICATION
for Research on Cancer (IARC) presents a global OFTUMOURS(BLUEBOOKS)
surveillance framework for monitoring the core
components of cancer control, illustrating both the unique
role of cancer registries and commonalities with the
surveillanceofothernoncommunicablediseases.

PierosM,ZnaorA,MeryL,BrayF
A global cancer surveillance framework within
noncommunicable disease surveillance: making the case EuropeanCodeAgainstCancer
forpopulationbasedcancerregistries
EpidemiologicReviews.Publishedonline2May2017
https://doi.org/10.1093/epirev/mxx003

Readarticle

http://www.iarc.fr/ 1/3
2017518 IARCINTERNATIONALAGENCYFORRESEARCHONCANCER

Obesityandhighinsulinlevels:twoimportantriskfactors
forpancreaticcancer

IARCandPAHOhostmeetingtodevelopcancerprevention EPICStudy
messagesforLatinAmerica

Latestdatashowaglobalincreaseof13%inchildhood CancerToday
cancerincidenceovertwodecades
ESTIMATEDCANCER
INCIDENCE,
IARCMonographsVolume118:Evaluationofwelding, MORTALITYANDPREVALENCE
WORLDWIDEIN2012
weldingfumes,andsomerelatedchemicals
CancerTodayispartoftheGlobalCancer
AllIARCNews
Observatorywebsite.

FACTSHEETS
PressReleases
Selectacancer
Latestdatashowaglobalincreaseof13%inchildhood
cancerincidenceovertwodecades Selectacountryorregion

12/04/2017
Readmore

AffordablevaccineskeytoscaleupHPVvaccination
andpreventthousandsofavoidablecervicalcancers

02/02/2017
Readmore

IARCWelcomePack
IARCstudyidentifiesnewgeneticfactorslinkedtoHPV
relatedcancers

CncernaAmricaCentraledoSulumaanlise
abrangente

AllReleases

Publications

CommonMinimumTechnicalStandardsandProtocols
forBiobanksDedicatedtoCancerResearch

15/05/2017
Biobankinghasdevelopedatarapidpace
in recent years, initiated by the drive for
personalizedmedicine,theneedforhigh
quality biological resources and
associated data for scientific research,
and technological advancement of
analytical platforms for molecular and
geneticresearch.
This book includes guidelines and
recommendationsforbiobanksnotonlyin
highincome countries but also in low and middleincome
countries (LMICs). The recommendations are based on
validatedand/orevidencebasedguidelines.
The book also includes sections on sample sharing, ethical,
legal, and social issues (ELSI), and harmonization guidelines

http://www.iarc.fr/ 2/3
2017518 IARCINTERNATIONALAGENCYFORRESEARCHONCANCER
importanttosupportcollaborativeresearcheffortsthatmake
useofbiologicalmaterials.
Readmore

IARCScientificPublications

WHO/IARCClassificationofTumours

AllPublications

IARC,150CoursAlbertThomas,69372LyonCEDEX08,FranceTel:+33(0)472738485
PrivacyPolicyIARC2017AllRightsReserved.

http://www.iarc.fr/ 3/3
2017518 FactSheetsbyPopulation

ABOUT DATA SOURCES AND METHODS FACT SHEETS ONLINE ANALYSIS HELP

Youarehere:Home/FactSheets/PopulationFactSheets

World

Men
Women
Bothsexes WORLD
Summarystatistics

Estimatedagestandardisedincidenceandmortalityrates:men

Estimatedincidence,mortalityand5yearprevalence:men

Incidence Mortality 5yearprevalence
Cancer
Number (%) ASR(W) Number (%) ASR(W) Number (%) Prop.
Lip,oralcavity 198975 2.7 5.5 97940 2.1 2.7 467157 3.1 18.0
Nasopharynx 60896 0.8 1.7 35756 0.8 1.0 161899 1.1 6.2
Otherpharynx 115131 1.6 3.2 77598 1.7 2.2 251118 1.6 9.7
Oesophagus 323008 4.4 9.0 281217 6.0 7.7 336535 2.2 13.0
Stomach 631293 8.5 17.4 468970 10.1 12.8 1030787 6.7 39.7
Colorectum 746298 10.1 20.6 373639 8.0 10.0 1953431 12.8 75.3
Liver 554369 7.5 15.3 521041 11.2 14.3 453345 3.0 17.5
Gallbladder 76844 1.0 2.1 60339 1.3 1.6 90368 0.6 3.5
Pancreas 178161 2.4 4.9 173827 3.7 4.8 114434 0.7 4.4
Larynx 138102 1.9 3.9 73261 1.6 2.0 388593 2.5 15.0
Lung 1241601 16.8 34.2 1098702 23.6 30.0 1266696 8.3 48.8
Melanomaofskin 120649 1.6 3.3 31390 0.7 0.9 452674 3.0 17.4
A
Kaposisarcoma 29022 0.4 0.8 17358 0.4 0.5 55337 0.4 2.1
Prostate 1094916 14.8 30.7 307481 6.6 7.8 3857500 25.2 148.6
Testis 55266 0.7 1.5 10351 0.2 0.3 214666 1.4 8.3
Kidney 213924 2.9 6.0 90802 2.0 2.5 580700 3.8 22.4
Bladder 330380 4.5 9.0 123051 2.6 3.2 1018415 6.7 39.3
Brain,nervoussystem 139608 1.9 3.9 106376 2.3 3.0 190011 1.2 7.3
Thyroid 68179 0.9 1.9 12626 0.3 0.3 271270 1.8 10.4
Hodgkinlymphoma 38520 0.5 1.1 15463 0.3 0.4 108301 0.7 4.2
NonHodgkinlymphoma 217643 2.9 6.0 115404 2.5 3.1 463368 3.0 17.9
Multiplemyeloma 62469 0.8 1.7 43091 0.9 1.2 124985 0.8 4.8
Leukaemia 200676 2.7 5.6 151321 3.3 4.2 284797 1.9 11.0
Allcancersexcl.nonmelanomaskincancer 7410376 100.0 204.9 4653385 100.0 126.3 15296119 100.0 589.4
http://globocan.iarc.fr/Pages/fact_sheets_population.aspx 1/6
2017518 FactSheetsbyPopulation
Allcancersexcl.nonmelanomaskincancer 7410376 100.0 204.9 4653385 100.0 126.3 15296119 100.0 589.4
Incidenceandmortalitydataforallages.5yearprevalenceforadultpopulationonly.
ASR(W)andproportionsper100,000.

GLOBOCAN2012(IARC)SectionofCancerSurveillance(19/5/2017)
Men
Women
Bothsexes
Summarystatistics
WORLD
Estimatedagestandardisedincidenceandmortalityrates:women

http://globocan.iarc.fr/Pages/fact_sheets_population.aspx 2/6
2017518 FactSheetsbyPopulation

Estimatedincidence,mortalityand5yearprevalence:women

Incidence Mortality 5yearprevalence
Cancer
Number (%) ASR(W) Number (%) ASR(W) Number (%) Prop.
Lip,oralcavity 101398 1.5 2.5 47413 1.3 1.2 234992 1.4 9.1
Nasopharynx 25795 0.4 0.7 15075 0.4 0.4 66799 0.4 2.6
Otherpharynx 27256 0.4 0.7 18507 0.5 0.5 58873 0.3 2.3
Oesophagus 132776 2.0 3.1 118952 3.4 2.7 127528 0.7 4.9
Stomach 320301 4.8 7.5 254103 7.2 5.7 507340 3.0 19.5
Colorectum 614304 9.2 14.3 320294 9.0 6.9 1590151 9.3 61.2
Liver 228082 3.4 5.3 224492 6.3 5.1 179825 1.0 6.9
Gallbladder 101257 1.5 2.3 82484 2.3 1.8 115278 0.7 4.4
Pancreas 159711 2.4 3.6 156564 4.4 3.4 97110 0.6 3.7
Larynx 18775 0.3 0.5 10115 0.3 0.2 53082 0.3 2.0
Lung 583100 8.8 13.6 491223 13.8 11.1 626382 3.7 24.1
Melanomaofskin 111481 1.7 2.8 24098 0.7 0.6 417080 2.4 16.1 A
Kaposisarcoma 15225 0.2 0.4 9616 0.3 0.3 25058 0.1 1.0
Breast 1671149 25.1 43.1 521907 14.7 12.9 6232108 36.3 239.9
Cervixuteri 527624 7.9 14.0 265672 7.5 6.8 1547161 9.0 59.6
Corpusuteri 319605 4.8 8.3 76160 2.1 1.8 1216504 7.1 46.8
Ovary 238719 3.6 6.1 151917 4.3 3.8 586624 3.4 22.6
Kidney 123936 1.9 3.0 52604 1.5 1.2 326046 1.9 12.6
Bladder 99413 1.5 2.2 42033 1.2 0.9 301334 1.8 11.6
Brain,nervoussystem 116605 1.8 3.0 83006 2.3 2.1 152903 0.9 5.9
Thyroid 229923 3.5 6.1 27145 0.8 0.6 934805 5.4 36.0
Hodgkinlymphoma 27430 0.4 0.7 10006 0.3 0.3 80237 0.5 3.1
NonHodgkinlymphoma 168098 2.5 4.1 84266 2.4 2.0 369475 2.2 14.2
Multiplemyeloma 51782 0.8 1.2 36928 1.0 0.8 104483 0.6 4.0
Leukaemia 151289 2.3 3.9 114150 3.2 2.8 216137 1.3 8.3
Allcancersexcl.nonmelanomaskincancer 6657518 100.0 165.2 3548190 100.0 82.9 17159060 100.0 660.5
Incidenceandmortalitydataforallages.5yearprevalenceforadultpopulationonly.
ASR(W)andproportionsper100,000.

http://globocan.iarc.fr/Pages/fact_sheets_population.aspx 3/6
2017518 FactSheetsbyPopulation

GLOBOCAN2012(IARC)SectionofCancerSurveillance(19/5/2017)
Men

WORLD
Women
Bothsexes
Summarystatistics

Estimatedagestandardisedincidenceandmortalityrates:bothsexes

Estimatedincidence,mortalityand5yearprevalence:bothsexes

Incidence Mortality 5yearprevalence
Cancer
Number (%) ASR(W) Number (%) ASR(W) Number (%) Prop.
Lip,oralcavity 300373 2.1 4.0 145353 1.8 1.9 702149 2.2 13.5
Nasopharynx 86691 0.6 1.2 50831 0.6 0.7 228698 0.7 4.4
Otherpharynx 142387 1.0 1.9 96105 1.2 1.3 309991 1.0 6.0
Oesophagus 455784 3.2 5.9 400169 4.9 5.0 464063 1.4 8.9
Stomach 951594 6.8 12.1 723073 8.8 8.9 1538127 4.7 29.6
Colorectum 1360602 9.7 17.2 693933 8.5 8.4 3543582 10.9 68.2
Liver 782451 5.6 10.1 745533 9.1 9.5 633170 2.0 12.2
Gallbladder 178101 1.3 2.2 142823 1.7 1.7 205646 0.6 4.0
Pancreas 337872 2.4 4.2 330391 4.0 4.1 211544 0.7 4.1
http://globocan.iarc.fr/Pages/fact_sheets_population.aspx 4/6
2017518 FactSheetsbyPopulation
Larynx 156877 1.1 2.1 83376 1.0 1.1 441675 1.4 8.5
Lung 1824701 13.0 23.1 1589925 19.4 19.7 1893078 5.8 36.5
Melanomaofskin 232130 1.7 3.0 55488 0.7 0.7 869754 2.7 16.8 A
Kaposisarcoma 44247 0.3 0.6 26974 0.3 0.3 80395 0.2 1.5
Breast 1671149 11.9 43.1 521907 6.4 12.9 6232108 19.2 239.9
Cervixuteri 527624 3.8 14.0 265672 3.2 6.8 1547161 4.8 59.6
Corpusuteri 319605 2.3 8.3 76160 0.9 1.8 1216504 3.7 46.8
Ovary 238719 1.7 6.1 151917 1.9 3.8 586624 1.8 22.6
Prostate 1094916 7.8 30.7 307481 3.7 7.8 3857500 11.9 148.6
Testis 55266 0.4 1.5 10351 0.1 0.3 214666 0.7 8.3
Kidney 337860 2.4 4.4 143406 1.7 1.8 906746 2.8 17.5
Bladder 429793 3.1 5.3 165084 2.0 1.9 1319749 4.1 25.4
Brain,nervoussystem 256213 1.8 3.4 189382 2.3 2.5 342914 1.1 6.6
Thyroid 298102 2.1 4.0 39771 0.5 0.5 1206075 3.7 23.2
Hodgkinlymphoma 65950 0.5 0.9 25469 0.3 0.3 188538 0.6 3.6
NonHodgkinlymphoma 385741 2.7 5.1 199670 2.4 2.5 832843 2.6 16.0
Multiplemyeloma 114251 0.8 1.5 80019 1.0 1.0 229468 0.7 4.4
Leukaemia 351965 2.5 4.7 265471 3.2 3.4 500934 1.5 9.6
Allcancersexcl.nonmelanomaskincancer 14067894 100.0 182.0 8201575 100.0 102.4 32455179 100.0 625.0
Incidenceandmortalitydataforallages.5yearprevalenceforadultpopulationonly.
ASR(W)andproportionsper100,000.

GLOBOCAN2012(IARC)SectionofCancerSurveillance(19/5/2017)
Men
http://globocan.iarc.fr/Pages/fact_sheets_population.aspx 5/6
2017518 FactSheetsbyPopulation
Men
Women
Bothsexes WORLD
Summarystatistics

Summarystatistics(2012)
WORLD Male Female Bothsexes
Population(thousands) 3557717 3496728 7054446
Numberofnewcancercases(thousands) 7410.4 6657.5 14067.9
Agestandardisedrate(W) 204.9 165.2 182.0
Riskofgettingcancerbeforeage75(%) 21.0 16.4 18.5

Numberofcancerdeaths(thousands) 4653.4 3548.2 8201.6

Agestandardisedrate(W) 126.3 82.9 102.4
Riskofdyingfromcancerbeforeage75(%) 12.7 8.4 10.5

5yearprevalentcases,adultpopulation(thousands) 15296.1 17159.1 32455.2

Proportion(per100,000) 589.4 660.5 625.0

5mostfrequentcancers(rankingdefinedbytotalnumberofcases)
Lung Breast Lung
Prostate Colorectum Breast
Colorectum Lung Colorectum
Stomach Cervixuteri Prostate
Liver Stomach Stomach

Datasourcesandmethods
Incidence

Method:Populationweightedaverageoftheareaspecificratesappliedtothe2012areapopulation.
Mortality

Method:Populationweightedaverageoftheareaspecificratesappliedtothe2012areapopulation.
Prevalence
Sumofareaspecificprevalentcases

Glossary
Agestandardisedrate(W):
Arateisthenumberofnewcasesordeathsper100000personsperyear.Anagestandardisedrateistheratethatapopulationwouldhaveifit
hadastandardagestructure.Standardizationisnecessarywhencomparingseveralpopulationsthatdifferwithrespecttoagebecauseagehasa
powerfulinfluenceontheriskofcancer.
Riskofgettingordyingfromthediseasebeforeage75(%):
Theprobabilityorriskofindividualsgetting/dyingfromcancer.Itisexpressedasthenumberofnewbornchildren(outof100)whowouldbe
expectedtodevelop/diefromcancerbeforetheageof75iftheyhadcancerrates(intheabsenceofothercausesofdeath).

Permalink|Print

IARC,150CoursAlbertThomas,69372LyonCEDEX08,FranceTel:+33(0)472738485Fax:+33(0)472738575
IARC2017AllRightsReserved.

http://globocan.iarc.fr/Pages/fact_sheets_population.aspx 6/6